Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Xylem Inc.
Bear Case (25th pct.)
-34.9% vs price
Base Case (Median)
-32.4% vs price
Bull Case (75th pct.)
-28.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $73.32 | -30.6% | High (40%) |
| PE Comparable | $80.95 | -23.4% | Medium (25%) |
| Growth Trajectory DCF | $69.86 | -33.9% | Medium (20%) |
| Graham Number | $67.76 | -35.9% | High (80%) |
| EV/EBITDA | $71.48 | -32.4% | Medium (20%) |
| EV/FCF | $76.90 | -27.2% | Medium (20%) |
| Earnings Power Value | $42.78 | -59.5% | High (70%) |
Based on 7 out of 8 methods, XYL appears overvalued at the current price of $105.69. The base case fair value of $71.48 implies 32.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.